China's Pharmaceutical Industry Adheres to Innovation Leadership, And Innovation-driven Transformation Has Achieved Initial Success

The target for R&D investment in the 13th Five-Year Plan formulated in 2016 is: by 2020, the R&D investment intensity of enterprises above the scale of the industry will reach more than 2%. The quality of innovation will be significantly improved, new drug registrations will account for a greater proportion of drug registrations, a number of high-quality innovations will be industrialised, and breakthroughs in international registration of new drugs will be achieved. 

During the Thirteenth Five-Year Plan period, investment in pharmaceutical R&D will continue to grow, with an average annual increase of about 8% in R&D investment by enterprises above the scale. The proportion of R&D expenditure of listed companies to sales revenue will exceed 6% in 2020. The number of new drugs under development The number of new drugs under development has jumped to the second place in the world, with more than 1,000 new drugs filed for clinical application and 47 domestic innovative drugs approved for marketing, doubling the number of the 12th Five-Year Plan. The number of new drugs in research and development will be the second largest in the world, with more than 1,000 new drugs declared for clinical use and 47 domestic innovative drugs approved for marketing, doubling the number of new drugs in the 12th Five-Year Plan. A number of high-end products in the fields of medical devices, pharmaceutical equipment and production consumables A number of high-end products in the fields of medical devices, pharmaceutical equipment and production consumables have filled the gaps in China. However, China's original innovation capacity in frontier areas is insufficient, and the institutional mechanism for collaborative innovation between industry, academia, research and medicine still needs to be improved. However, China's original innovation capacity in frontier areas is insufficient, and the institutional mechanism for collaborative innovation between industry, academia, research and medicine still needs to be improved. 

The 14th Five-Year Plan further emphasises the basic principle of adherence to innovation leadership

At present, domestic and foreign countries are facing a new round of technological changes and cross-border integration accelerated background environment, around the new mechanism, new target drug The breakthroughs in basic research and translational applications of new mechanisms and new targets have been continuously achieved, and the deep integration of biomedicine and new-generation information technology The new generation of biotechnology, represented by gene therapy, cell therapy, synthetic biotechnology, bifunctional antibodies, etc., is becoming increasingly mature, providing a new opportunity for the pharmaceutical industry to develop a new generation of biotechnology. This has provided a wide scope for the pharmaceutical industry to seize the opportunities of the new round of technological revolution and industrial change. This provides a wide space for the pharmaceutical industry to seize the opportunities of the new round of technological revolution and industrial transformation. China's pharmaceutical industry should adhere to innovation to lead the way and make innovation the core task to promote the high quality development of the pharmaceutical industry. We should accelerate the implementation of the innovation-driven development strategy, build an open innovation eco-system, improve the quality and efficiency of innovation, and speed up the implementation of the innovation-driven development strategy. The new engine for the sustainable and healthy development of the pharmaceutical industry will be built. The new engine for the sustainable and healthy development of the pharmaceutical industry. 

The overall target of the innovation drive in the 14th Five-Year Plan for 2022 is: the average annual growth of R&D investment in the industry is more than 10%; by 2025, the ratio of new sales of innovative products to the incremental revenue of the industry is more than 10%. By 2025, the ratio of new sales of innovative products to the industry's incremental business revenue will be further increased. By 2025, the proportion of new sales of innovative products to the industry's incremental business revenue will be further increased.